Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of...
AYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is...
Aytu BioPharma: Helping children get off to a healthier start and a better life. Aytu is committed to improving the health of all children. We’re developing a portfolio of products to help children be their best and now expanding into ADHD. Our Adult and consumer health products remain an important part of our heritage, while we study COVID-19 treatments and...